12 - 15% of hypertensive patients develop Resistant Hypertension1

1.9% developed resistant hypertension within a median of 1.5 years from initial treatment (study based)2


Patients with Resistant Hypertension are at an Increased risk of3


Coronary Heart Disease

(HR:1.44 times)


(HR:1.57 times)

All-Cause Mortality

(HR:1.30 times)

Heart Failure

(HR:1.88 times)

Pulmonary Artery Disease

(HR:1.23 times)

End-Stage Renal Disease

(HR:1.95 times)

Ambulatory BP monitoring (ABPM) Mandatory in Diagnosing Resistant Hypertension

American heart Association Defines:

Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes, commonly including a long-acting calcium channel blocker, a blocker of the renin-angiotensin system (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), and a diuretic.
The antihypertensive drugs should be administered at maximum or maximally tolerated daily doses.
RH also includes patients whose BP achieves target values on ≥4 antihypertensive medications.

Old age (>55 years age) is the strongest5 predictor of Resistant Hypertension

The Other6 predominant factors are:



High baseline blood pressure

Leading factors7,9 that contribute to the development of Hypertension and Resistant Hypertension



Physical inactivity

A diet high in

Heavy alcohol intake

Secondary Causes10,11 of Resistant Hypertension

Steps for Diagnosis of Resistant Hypertension

Use good blood pressure measurement technique with validation of the accuracy of readings for accurate diagnosis of resistant hypertension14.
Exclude Pseudo resistance.
Confirm adherence
antihypertensive therapy.
Perform 24 hour ambulatory BP monitoring (if unavailable, use home BP monitoring) to exclude white coat effect.
Assess for secondary hypertension.
Assess for target organ damage.

Therapy Guidelines

American Heart Association 2018 Guideline recommends 16
ARB + CCB + Diuretic (or loop diuretic)
As the first line treatment of resistant hypertension.

For GFR > 30 Ml/min - the diuretics with the greatest evidence base for reducing cardiovascular outcomes are the thiazide-like diuretics chlorthalidone. 18,19

For GFR < 30ml/min-A long-acting loop diuretic such as torsemide is favourable over shorter-acting agents such as bumetanide or furosemide. 17


Azilsartan is the choice of ARB


Long-acting Nifedipine superior to Amlodipine


Long-acting Nifedipine is the preferred choice of CCB in RHT2


Torsemide is the choice of diuretic for eGFR below 30 ml/min/1.73m2

The One Stop Solution…
In the Management of Tough to Control BP

Latest Posts

Analyzing Resistant hypertension: An insight into its etiology, prevalence, risk factors and management

Controlling Hypertension with Azilsartan: Recent Advances

Managing Difficult to Treat Hypertension with Newer ARBs

Prompt BP Control with an Early Combination Therapy: Role of a Fixed-Dose Combination

Contact us
for further information


1. Wolf-Maier et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289, 2363–2369 (2003).2. Daugherty SL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–1642. 3. Muntner Petal.ALLHAT Collaborative Research Group: Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 64: 1012–1021, 2014pmid:25259745.4. Muntner Petal.ALLHAT Collaborative Research Group: Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 64: 1012–1021, 2014pmid:25259745.5. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Rocella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000; 36: 594–599.6. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002; 4: 393–404. Crossref.7. Nishizaka MK et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18:805–812.8. He FJ et al. Effect of longer-term modest salt reduction onblood pressure. The Cochrane Database of Systemic Reviews. 2004;(3): 9. Henningsen NC et al. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med Scand.1980;207:245–251. 10. J. P. Garg et al. Resistant hypertension revisited: a comparison of two university-based cohorts; American Journal of Hypertension, vol. 18, no. 5, pp. 619–626, 2005. 11. Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003, 289:2560-2572. 10.1001/jama.289.19.2560. 12. Whelton PK et al.: 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary:a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2018, 138:426-483. 13. Chapman N et al.Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007,49:839-845. 14. Pickering TG et al.Recommendations of blood pressure measurement in humans and experimental animals. Part 1:blood pressure measurement in humans. A Statement for Professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. 15. Egan BM et al.Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2016;18:817–824. 16. Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.